HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Shestakova Selected Research

insulin aspart protamine drug combination 30:70 insulin aspart

6/2009Intensification to biphasic insulin aspart 30/70 (BIAsp 30, NovoMix 30) can improve glycaemic control in patients treated with basal insulins: a subgroup analysis of the IMPROVE observational study.
4/2009Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study.
3/2009Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study.
11/2008The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.
7/2008When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study.
3/2008Biphasic insulin aspart 30 treatment improves glycaemic control in patients with type 2 diabetes in a clinical practice setting: experience from the PRESENT study.
3/2008Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study.
12/2007Transferring type 2 diabetes patients with uncontrolled glycaemia from biphasic human insulin to biphasic insulin aspart 30: experiences from the PRESENT study.
1/2006Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Shestakova Research Topics

Disease

12Type 2 Diabetes Mellitus (MODY)
01/2019 - 01/2006
2Body Weight (Weight, Body)
04/2009 - 01/2006
1Fetal Growth Retardation (Intrauterine Growth Retardation)
08/2020
1Hypertension (High Blood Pressure)
08/2020
1Premature Obstetric Labor (Premature Labor)
08/2020
1Pre-Eclampsia (Preeclampsia)
08/2020
1Proteinuria
08/2020
1Insulin Resistance
01/2019
1Obesity
01/2019
1Fibrosis (Cirrhosis)
01/2019
1Drug-Related Side Effects and Adverse Reactions
04/2009

Drug/Important Bio-Agent (IBA)

9insulin aspart protamine drug combination 30:70 insulin aspartIBA
06/2009 - 01/2006
6Insulin (Novolin)FDA Link
01/2019 - 12/2007
2Blood Glucose (Blood Sugar)IBA
10/2009 - 04/2009
2Metformin (Glucophage)FDA LinkGeneric
04/2009 - 01/2006
1Progestins (Progestagens)IBA
08/2020
1DydrogesteroneFDA Link
08/2020
1Matrix Metalloproteinases (MMPs)IBA
01/2019
1MicroRNAs (MicroRNA)IBA
01/2019
1InsulinsIBA
06/2009
1Insulin Glargine (Lantus)FDA Link
04/2009
1Glucose (Dextrose)FDA LinkGeneric
04/2009
1Hypoglycemic Agents (Hypoglycemics)IBA
04/2009
1Glyburide (Glibenclamide)FDA LinkGeneric
01/2006
12'- deoxythymidylyl- (3'- 5')- 2'- deoxyadenosine (d(AT))IBA
01/2006

Therapy/Procedure

6Therapeutics
06/2009 - 03/2008